{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:22:30Z","timestamp":1794439350761,"version":"4.9.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide\/ glucagon-like peptide-1 receptor agonist, is approved in the United States, Europe and Japan for the treatment of type 2 diabetes. Across the SURPASS-1 to -5 clinical studies, tirzepatide 5, 10 and 15\u00a0mg demonstrated significant improvements in glycated haemoglobin A1c (HbA1c) (\u2212\u00a01.9 to \u2212\u00a02.6%), body weight (\u2212\u00a06.6 to \u2212\u00a013.9%) and systolic blood pressure (SBP) (\u2212\u00a02.8 to \u2212\u00a012.6\u00a0mmHg) at the end of study treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Post-hoc mediation analyses were conducted to evaluate weight-loss dependent and weight-loss independent effects of tirzepatide on SBP reductions across the 5 SURPASS studies. The safety population (all randomized patients who took at least 1 dose of study drug) of each study was analyzed. Additional analyses were conducted at individual study level or pooled across 5 SURPASS trials.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The difference in mean SBP change from baseline at 40\u00a0weeks (total effect) between the tirzepatide and comparator groups was \u2212\u00a01.3 to \u2212\u00a05.1\u00a0mmHg (tirzepatide 5\u00a0mg), \u2212\u00a01.7 to \u2212\u00a06.5\u00a0mmHg (tirzepatide 10\u00a0mg) and \u2212\u00a03.1 to \u2212\u00a011.5\u00a0mmHg (tirzepatide 15\u00a0mg). These SBP reductions were primarily mediated through weight loss, with different degrees of contributions from weight-loss independent effects across the different trials. In the SURPASS-4 study, which enrolled patients with established cardiovascular disease, weight-loss independent effects explained 33% to 57% of difference in SBP change between tirzepatide and insulin glargine groups. In a pooled analysis of the SURPASS-1 to -5 studies, there was a significant (p\u2009&lt;\u20090.001) but weak correlation (r\u2009=\u20090.18 to 0.22) between change in body weight and SBP. Reductions in SBP with tirzepatide were not dependent on concomitant antihypertensive medications at baseline as similar reductions were observed whether participants were receiving them or not (interaction p\u2009=\u20090.77). The largest SBP reductions were observed in the highest baseline category (&gt;\u2009140\u00a0mmHg), while those in the first quartile of baseline SBP category (&lt;\u2009122\u00a0mmHg) observed no further decrease in SBP.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Tirzepatide-induced SBP reduction was primarily mediated through weight loss, with different degrees of contributions from weight-loss independent effects across the different trials. SBP reduction was not dependent on antihypertensive medication use but dependent on baseline SBP value, alleviating theoretical concerns of hypotension.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-023-01797-5","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T19:02:58Z","timestamp":1679684578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program"],"prefix":"10.1186","volume":"22","author":[{"given":"Ildiko","family":"Lingvay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofri","family":"Mosenzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Fern\u00e1ndez Land\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiren","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,24]]},"reference":[{"issue":"5","key":"1797_CR1","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.cjca.2017.12.005","volume":"34","author":"JR Petrie","year":"2018","unstructured":"Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018;34(5):575\u201384.","journal-title":"Can J Cardiol"},{"key":"1797_CR2","unstructured":"Organisation WH. Hypertension\u2014Key facts. 2021."},{"key":"1797_CR3","doi-asserted-by":"publisher","first-page":"4504287","DOI":"10.1155\/2018\/4504287","volume":"2018","author":"MH Arambewela","year":"2018","unstructured":"Arambewela MH, et al. Prevalence of chronic complications, their risk factors, and the cardiovascular risk factors among patients with type 2 diabetes attending the diabetic clinic at a Tertiary Care Hospital in Sri Lanka. J Diabetes Res. 2018;2018:4504287.","journal-title":"J Diabetes Res"},{"issue":"9","key":"1797_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.2337\/dci17-0026","volume":"40","author":"IH de Boer","year":"2017","unstructured":"de Boer IH, et al. Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(9):1273\u201384.","journal-title":"Diabetes Care"},{"key":"1797_CR5","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice C. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022; 45(Suppl 1): S144\u2013S174.","DOI":"10.2337\/dc22-S010"},{"issue":"2","key":"1797_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255\u2013323.","journal-title":"Eur Heart J"},{"issue":"10193","key":"1797_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. 2019;394(10193):121\u201330.","journal-title":"The Lancet"},{"issue":"10157","key":"1797_CR8","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. The Lancet. 2018;392(10157):1519\u201329.","journal-title":"The Lancet"},{"issue":"19","key":"1797_CR9","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"4","key":"1797_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"key":"1797_CR11","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice C et al. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care. 2022; 45(Suppl 1): S125\u2013S143.","DOI":"10.2337\/dc22-S009"},{"key":"1797_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","volume":"355","author":"HC Gerstein","year":"2000","unstructured":"Gerstein HC, Mann JF, Hoogwerf B, Zinman B, Held C, Fisher M, Wolffenbuttel B, Bosch J, Richardson L, Pogue J, Heart Outcomes Prevention Evolution (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253\u20139.","journal-title":"Lancet"},{"issue":"6","key":"1797_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jama.2014.18574","volume":"313","author":"CA Emdin","year":"2015","unstructured":"Emdin CA, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313(6):603\u201315.","journal-title":"JAMA"},{"issue":"10022","key":"1797_CR14","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet. 2016;387(10022):957\u201367.","journal-title":"The Lancet"},{"key":"1797_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i717","volume":"352","author":"M Brunstrom","year":"2016","unstructured":"Brunstrom M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016;352: i717.","journal-title":"BMJ"},{"issue":"10285","key":"1797_CR16","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","volume":"397","author":"K Rahimi","year":"2021","unstructured":"Rahimi K, et al. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. The Lancet. 2021;397(10285):1625\u201336.","journal-title":"The Lancet"},{"issue":"10295","key":"1797_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet. 2021;398(10295):143\u201355.","journal-title":"The Lancet"},{"issue":"6","key":"1797_CR18","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503\u201315.","journal-title":"N Engl J Med"},{"issue":"10300","key":"1797_CR19","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","volume":"398","author":"B Ludvik","year":"2021","unstructured":"Ludvik B, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet. 2021;398(10300):583\u201398.","journal-title":"The Lancet"},{"issue":"10313","key":"1797_CR20","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del Prato S, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet. 2021;398(10313):1811\u201324.","journal-title":"The Lancet"},{"issue":"6","key":"1797_CR21","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jama.2022.0078","volume":"327","author":"D Dahl","year":"2022","unstructured":"Dahl D, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534\u201345.","journal-title":"JAMA"},{"issue":"1","key":"1797_CR22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","volume":"21","author":"MA Nauck","year":"2022","unstructured":"Nauck MA, D\u2019Alessio DA. Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022;21(1):169.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"1797_CR23","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1161\/HYP.0000000000000202","volume":"78","author":"ME Hall","year":"2021","unstructured":"Hall ME, et al. Weight-loss strategies for prevention and treatment of hypertension: a scientific statement from the American Heart Association. Hypertension. 2021;78(5):e38\u201350.","journal-title":"Hypertension"},{"issue":"3","key":"1797_CR24","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","volume":"28","author":"N Sattar","year":"2022","unstructured":"Sattar N, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591\u20138.","journal-title":"Nat Med"},{"issue":"3","key":"1797_CR25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jdiacomp.2014.01.009","volume":"28","author":"VA Fonseca","year":"2014","unstructured":"Fonseca VA, et al. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. J Diabetes Complications. 2014;28(3):399\u2013405.","journal-title":"J Diabetes Complications"},{"issue":"1","key":"1797_CR26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/ajh\/hpt196","volume":"27","author":"M Katout","year":"2014","unstructured":"Katout M, et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Am J Hypertens. 2014;27(1):130\u20139.","journal-title":"Am J Hypertens"},{"issue":"5","key":"1797_CR27","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1161\/HYP.0000000000000202","volume":"78","author":"ME Hall","year":"2021","unstructured":"Hall ME, Faha M, Cohen JB, Ard JD, Egan BM, Hall JE, Lavie CJ, Ma J, Ndumele CE, Schauer PR, Shimbo D, on behalf of the American Heart Association Council on Hypertension; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometabolic Health; and Stroke Council. Weight-loss strategies for prevention and treatment of hypertension: a scientific statement from the American Heart Association. Hypertension. 2021;78(5):e38\u201350.","journal-title":"Hypertension"},{"issue":"12","key":"1797_CR28","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1172\/JCI21625","volume":"114","author":"S Furukawa","year":"2004","unstructured":"Furukawa S, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114(12):1752\u201361.","journal-title":"J Clin Invest"},{"issue":"2","key":"1797_CR29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1161\/01.HYP.0000137982.10191.0a","volume":"44","author":"AM Sironi","year":"2004","unstructured":"Sironi AM, et al. Visceral fat in hypertension: influence on insulin resistance and beta-cell function. Hypertension. 2004;44(2):127\u201333.","journal-title":"Hypertension"},{"issue":"6","key":"1797_CR30","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","volume":"10","author":"A Gastaldelli","year":"2022","unstructured":"Gastaldelli A, et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10(6):393\u2013406.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"1797_CR31","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","volume":"10","author":"T Heise","year":"2022","unstructured":"Heise T, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022;10(6):418\u201329.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1797_CR32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2337\/dbi20-0049","volume":"71","author":"JR Ussher","year":"2022","unstructured":"Ussher JR, et al. Cardiovascular effects of incretin-based therapies: integrating mechanisms with cardiovascular outcome trials. Diabetes. 2022;71(2):173\u201383.","journal-title":"Diabetes"},{"issue":"2","key":"1797_CR33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1479164111404257","volume":"8","author":"T Gaspari","year":"2011","unstructured":"Gaspari T, et al. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE\u2212\/\u2212 mouse model. Diab Vasc Dis Res. 2011;8(2):117\u201324.","journal-title":"Diab Vasc Dis Res"},{"issue":"1","key":"1797_CR34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12933-022-01492-x","volume":"21","author":"CC van Ruiten","year":"2022","unstructured":"van Ruiten CC, et al. Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial. Cardiovasc Diabetol. 2022;21(1):63.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"1797_CR35","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/dme.12594","volume":"32","author":"BJ von Scholten","year":"2015","unstructured":"von Scholten BJ, et al. Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. Diabet Med. 2015;32(3):343\u201352.","journal-title":"Diabet Med"},{"issue":"1","key":"1797_CR36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/jch.13447","volume":"21","author":"MO Wijkman","year":"2019","unstructured":"Wijkman MO, et al. Predictors and correlates of systolic blood pressure reduction with liraglutide treatment in patients with type 2 diabetes. J Clin Hypertens (Greenwich). 2019;21(1):105\u201315.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1797_CR37","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2337\/db20-351-OR","volume":"69","author":"MB Christensen","year":"2020","unstructured":"Christensen MB, Filip K. Six-day subcutaneous GIP infusion increases glycemic time-in-range in patients with type 1 diabetes. Diabetes. 2020;69:351.","journal-title":"Diabetes"},{"key":"1797_CR38","unstructured":"Sorum N, et al. GIP infusion acutely decreases blood pressure and increases heart rate in men with type 2 diabetes, concomitantly with increased proatrial natriuretic peptide levels. In: Diabetologia. 2022; Springer, USA."},{"issue":"5","key":"1797_CR39","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1093\/cvr\/cvz323","volume":"116","author":"VD Heuvelman","year":"2020","unstructured":"Heuvelman VD, Van Raalte DH, Smits MM. Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes. Cardiovasc Res. 2020;116(5):916\u201330.","journal-title":"Cardiovasc Res"},{"issue":"11","key":"1797_CR40","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","volume":"10","author":"HJL Heerspink","year":"2022","unstructured":"Heerspink HJL, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(11):774\u201385.","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01797-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-023-01797-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01797-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T19:04:57Z","timestamp":1679684697000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-023-01797-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,24]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1797"],"URL":"https:\/\/doi.org\/10.1186\/s12933-023-01797-5","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,24]]},"assertion":[{"value":"12 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors consent to publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Ildiko Lingvay received research funding (paid to institution) from Novo Nordisk, Sanofi, Merck, Pfizer, Mylan and Boehringer Ingelheim. She received advisory\/consulting fees and\/or other support from: Novo Nordisk, Eli Lilly and Company, Sanofi, AstraZeneca, Boehringer Ingelheim, Janssen, Intercept, Intarcia, Target Pharma, Merck, Pfizer, Novartis, GI Dynamics, Mylan, Mannkind, Valeritas, Zealand Pharma, Shionogi, Carmot and Bayer. Ofri Mosenzon has received research grant support through Hadassah Hebrew University Hospital, Novo Nordisk and AstraZeneca. She received advisory\/consulting fees and\/or other support from Novo Nordisk, Eli Lilly and Company, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim, Novartis, AstraZeneca and BOL Pharma. She is on the speaker\u2019s bureau for Novo Nordisk, Eli Lilly and Company, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca and Janssen. Katelyn Brown, Xuewei Cui, Ciara O\u2019 Neill, Laura Fern\u00e1ndez Land\u00f3 and Hiren Patel are employees and shareholders of Eli Lilly and Company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"66"}}